Published in Med Clin (Barc) on February 12, 2000
Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract (2012) 1.10
"Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol (2008) 0.99
Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol (2009) 0.89
Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol (2008) 0.84
Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver (2012) 0.79
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) (2017) 0.75
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut (2010) 2.98
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther (2012) 2.25
Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med (2000) 1.96
Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther (2001) 1.80
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology (1997) 1.63
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther (2011) 1.63
Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol (1995) 1.52
Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Endoscopy (1995) 1.48
[Guidelines for the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding]. Gastroenterol Hepatol (2003) 1.47
Risk factors associated with refractory peptic ulcers. Gastroenterology (1995) 1.47
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol (2003) 1.44
Is 1-week treatment for peptic ulcer healing sufficient and safe? Rev Esp Enferm Dig (2000) 1.38
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther (2005) 1.34
Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther (2002) 1.33
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther (2000) 1.33
Identification of factors that influence tolerance of upper gastrointestinal endoscopy. Eur J Gastroenterol Hepatol (1999) 1.30
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther (2011) 1.22
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther (2011) 1.22
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2011) 1.21
Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem (1991) 1.20
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther (2004) 1.18
Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology (1999) 1.17
The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther (2011) 1.15
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.14
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol (1999) 1.14
Epinephrine injection versus epinephrine injection and a second endoscopic method in high risk bleeding ulcers. Cochrane Database Syst Rev (2007) 1.14
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther (2009) 1.14
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther (2007) 1.12
Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther (2008) 1.09
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther (2003) 1.08
Letter: the irony of oral iron - not an underdog for post-gastrointestinal bleeding anaemia. Aliment Pharmacol Ther (2014) 1.08
Meta-analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. Aliment Pharmacol Ther (2011) 1.07
H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev (2004) 1.07
Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (2012) 1.05
[Sedation in digestive endoscopy. Results of a hospital survey in Catalonia (Spain)]. Gastroenterol Hepatol (2004) 1.04
Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.02
Factors predicting failure of endoscopic injection therapy in bleeding duodenal ulcer. Gastrointest Endosc (1996) 1.01
Sebaceous carcinoma of the vulva. Am J Dermatopathol (1999) 1.01
Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther (2004) 0.99
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther (2002) 0.96
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Aliment Pharmacol Ther (2000) 0.96
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2008) 0.95
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther (1999) 0.93
Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut (1996) 0.93
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther (2013) 0.93
Adaptation of esophageal mucosa to acid- and pepsin-induced damage: role of nitric oxide and epidermal growth factor. Dig Dis Sci (1997) 0.93
Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther (2004) 0.92
Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol (2012) 0.91
Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology (1994) 0.90
Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther (2011) 0.90
Environmental risk factors and Crohn's disease: a population-based, case-control study in Spain. Dig Liver Dis (2001) 0.90
Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther (2003) 0.89
Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer (1990) 0.89
[Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study]. Gastroenterol Hepatol (2002) 0.89
Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther (2013) 0.89
[Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol (2006) 0.88
Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut (1996) 0.87
Urticarial reaction to oral polyethylene glycol electrolyte lavage solution. Gastrointest Endosc (1992) 0.87
Radiological diagnosis of inorganic lead poisoning. J Clin Gastroenterol (1989) 0.86
Usefulness of a delayed test for the diagnosis of Helicobacter pylori infection in bleeding peptic ulcer. Aliment Pharmacol Ther (2006) 0.86
Cytokine effects on pepsinogen secretion from human peptic cells. Gut (1997) 0.86
Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med (1990) 0.86
Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci (1989) 0.85
[Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease]. Gastroenterol Hepatol (2002) 0.84
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 0.84
Risk factors for ulcerative colitis: A population-based, case-control study in Spain. J Crohns Colitis (2008) 0.83
Gastric ulcer penetrating to the liver: endoscopic diagnosis. Am J Gastroenterol (1993) 0.83
Risk factors for advanced lesions undetected at prior colonoscopy: not always poor preparation. Endoscopy (2010) 0.83
[Ulcerative pancolitis predicts the need for colectomy: study of an incident cohort of patients with ulcerative colitis in Aragón (Spain)]. Gastroenterol Hepatol (2005) 0.82
Non-steroidal anti-inflammatory drugs and prostaglandin effects on pepsinogen secretion by dispersed human peptic cells. Gut (1995) 0.82
Value and limitations of cytologic criteria for the diagnosis of hepatocellular carcinoma by fine needle aspiration biopsy. Acta Cytol (1993) 0.82
High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther (2012) 0.81
Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol (1995) 0.81
Efficacy of low and standard midazolam doses for gastroscopy. A randomized, double-blind study. Eur J Gastroenterol Hepatol (2000) 0.81
[The role of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease]. Gastroenterol Hepatol (2003) 0.81
microRNA profiling in duodenal ulcer disease caused by Helicobacter pylori infection in a Western population. Clin Microbiol Infect (2012) 0.81
Limited usefulness of a seven-day twice-a-day quadruple therapy. Eur J Gastroenterol Hepatol (2000) 0.80
[Fulminant infection caused by varicella herpes zoster in patient with Crohn disease undergoing treatment with azathioprine]. Gastroenterol Hepatol (2001) 0.80
[CagA and VacA cytotoxin antibodies and risk for peptic ulcer disease in patients with Helicobacter pylori infection]. Med Clin (Barc) (2001) 0.79
Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. Int J Antimicrob Agents (2000) 0.79
[Comparison between two 13C-urea breath tests for the diagnosis of Helicobacter pylori infection: isotope ratio mass spectrometer versus infrared spectrometer]. Gastroenterol Hepatol (2003) 0.78
[Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. Gastroenterol Hepatol (1998) 0.78
[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy]. Med Clin (Barc) (2000) 0.78
[Evaluation of Helicobacter pylori susceptibility to rifaximin]. Gastroenterol Hepatol (2004) 0.78
Idiopathic pylephlebitis and idiopathic sclerosing peritonitis in a man with protein S deficiency. J Clin Gastroenterol (2001) 0.78
Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers--a cost-effectiveness analysis. Aliment Pharmacol Ther (2000) 0.78
Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. Eur J Med Chem (2013) 0.78
[Is the breath test reliable in primary care diagnosis of Helicobacter pylori infection?]. Aten Primaria (2003) 0.77
Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment. Rev Esp Enferm Dig (2003) 0.77
Surgical resection and survival in Western patients with hepatocellular carcinoma. J Hepatol (1992) 0.77
Diarrhea as a presenting symptom of hepatocellular carcinoma. Dig Dis Sci (1990) 0.77
Megacolon in Duchenne's disease. Gastroenterology (1982) 0.77
On dissonances, Helicobacter pylori and NSAIDs. Aliment Pharmacol Ther (2000) 0.77